The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: A prospective monitoring of UL97 and UL54 gene mutations

Transplant Infectious Disease

Volumn 16, Issue 6, 2014, Pages 919-929

  Choi, S H ^a,b,c   Hwang, J Y ^a,d   Park, K S ^a   Kim, Y ^a   Lee, S H ^e   Yoo, K H ^e   Kang, E S ^e   Ahn, J H ^e   Sung, K W ^e   Koo, H H ^e   Kim, Y J ^e  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Hallym University   (South Korea)

^d Korea University   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cytomegalovirus; Drug resistance; Ganciclovir kinase; Hematopoietic stem cell transplantation; UL54 protein

Indexed keywords

ANTIVIRAL AGENTS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; DRUG RESISTANCE, VIRAL; FEMALE; GENETICS; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MUTATION; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MUTATION;

EID: 84920147973     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12311     Document Type: Article

References (31)

1. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113 (23): 5711-5719.
2. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23 (4): 689-712.
3. Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011; 24 (6): 605-611.
4. Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci USA 1986; 83 (22): 8769-8773.
5. Chou S, Marousek G, Parenti DM, et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis 1998; 178 (2): 526-530.
6. Bowen EF, Cherrington JM, Lamy PD, Griffiths PD, Johnson MA, Emery VC. Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. J Med Virol 1999; 58 (4): 402-407.
7. Mendez JC, Sia IG, Tau KR, et al. Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 1999; 67 (5): 755-757.
8. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96 (9): 3286-3289.
9. Mousavi-Jazi M, Hokeberg I, Schloss L, et al. Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment. Transpl Infect Dis 2001; 3 (4): 195-202.
10. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010; 54 (6): 2371-2378.
11. Chou S. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. J Clin Virol 2011; 50 (4): 287-291.
12. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010; 65 (12): 2628-2640.
13. Arellano-Galindo J, Vazquez-Meraz E, Jimenez-Hernandez E, et al. The role of cytomegalovirus infection and disease in pediatric bone marrow transplant recipients in Mexico City in the context of viral drug resistance. Pediatr Transplant 2011; 15 (1): 103-111.
14. Kim YJ, Boeckh M, Cook L, et al. Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients. Transpl Infect Dis 2012; 14 (6): 611-617.
15. Shmueli E, Or R, Shapira MY, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis 2014; 209 (4): 551-561.
16. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8): 1094-1097.
17. Yi ES, Kim YJ. Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients. Yonsei Med J 2012; 53 (2): 393-400.
18. Oshima K, Kanda Y, Kako S, et al. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol 2008; 80 (10): 1769-1775.
19. Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005; 77 (3): 425-429.
20. Boivin G, Goyette N, Farhan M, Ives J, Elston R. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 2012; 53 (3): 208-213.
21. Shao PL, Lu MY, Liau YJ, Kao CL, Chang SY, Huang LM. Lack of resistance-associated mutations in UL54 and UL97 genes of circulating cytomegalovirus strains isolated in a medical center in Taiwan. J Formos Med Assoc 2012; 111 (8): 456-460.
22. Chou S, Boivin G, Ives J, Elston R. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. J Infect Dis 2014; 209 (8): 1219-1226.
23. Gohring K, Feuchtinger T, Mikeler E, et al. Dynamics of the emergence of a human cytomegalovirus UL97 mutant strain conferring ganciclovir resistance in a pediatric stem-cell transplant recipient. J Mol Diagn 2009; 11 (4): 364-368.
24. Jeong TD, Sung H, Choi SH, et al. Cytomegalovirus ventriculoencephalitis with compartmentalization of antiviral-resistant cytomegalovirus in a T cell-depleted haploidentical peripheral blood stem cell transplant recipient. Diagn Microbiol Infect Dis 2012; 74 (3): 307-310.
25. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15 (10): 1143-1238.
26. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97 (4): 867-874.
27. Park SY, Lee SO, Choi SH, et al. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. J Clin Microbiol 2011; 49 (12): 4179-4184.
28. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43 (1): 16-24.
29. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006; 7 (2): 125-130.
30. Vallejo C, Rios E, de la Serna J, et al. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Expert Rev Hematol 2011; 4 (1): 9-16.
31. Kim SJ, Moon JH, Kim H, et al. Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma 2012; 53 (8): 1515-1524.